11.11.25 -- Supporting The Next Generation Of ADCs

To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.

When partnering with CDMOs, success depends heavily on collaboration with a partner that combines deep technical expertise with a proven record of regulatory excellence and operational reliability.

Discover how a systematic approach to autologous cell therapy manufacturing can reduce costs, improve reliability, and accelerate access to life-changing treatments.

Choose a flexible and experienced CDMO to ensure seamless scalability, diverse process capabilities, and expert analytical support for your microbial protein production.

Explore the potential of targeting LILRB2/LILRB4 in cancer immunotherapy by delving into our findings on novel monoclonal antibodies that enhance anti-tumor immune responses.

Understand the benefits of using mRNA for vaccines and therapeutics, and learn how to address technical, intellectual property, and cost considerations when considering commercial production.

The journey of a novel bioconjugate into clinic is complex and uncertain. Explore the particular challenges when moving a bioconjugate candidate from early development into clinic.

Ready-to-use (RTU) components can simplify processing requirements for aseptic fill and finish by reducing the need for equipment, utilities, and product space.

The way a CDMO responds to a request for proposal provides significant insight into how the CDMO will approach a long-term collaboration.

CEO Kenneth Bilenberg discusses building a CDMO's success on trust, reliability, and true partnership. The path focuses on agility to support biologics growth and the reshoring of U.S. manufacturing.

Unprecedented capital investments of >$8bn expand capacity to improve patient access. Going beyond expansions, learn more about a holistic, globally harmonized operational ecosystem.

Review the development of a high-strength synthetic gene promoter that enhances titers and maintains exceptional product quality and expression stability to support more efficient biomanufacturing.

A panel of experts share potential pitfalls and lessons learned from their many years of experience across a wide array of projects in the cell and gene therapy space.

Explore how KBI Biopharma’s SUREtechnology Platform™, powered by Selexis®, accelerates the development of complex biologics from early stages to first-in-human (FIH) trials, focusing on both speed and quality.